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tion,1 platelet activation,2 and platelet loss3 all occur.
Platelet activation is a tightly regulated series of events
that culminates in platelet secretory release and aggre-
gation. Platelets respond to stimulation in 3 phases:
shape change, microaggregation (primary aggregation),
and macroaggregation (secondary aggregation). Platelet
counts performed with anticoagulants that preserve
microaggregates (eg, hirudin) are the unaggregated or
single platelet count because hematologic counters do
not count aggregates as platelets. The total platelet
count can be obtained by using an in vitro anticoagulant
that causes disaggregation (eg, ethylenediaminete-
traacetic acid [EDTA]).
We have demonstrated that in vivo heparinization
reduces the platelet count in hirudin-anticoagulated
blood4,5 by increasing existing platelet microaggrega-
T he effects of cardiopulmonary bypass on the plateletare still not fully understood, but platelet dysfunc-
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rected count was 142 ± 48 × 109 · L–1 (P = .6).
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platelet counts.6 At each sampling, after the dead space in the
sampling line had been cleared, the next 2 mL of blood was
discarded. The samples were divided: one part was anticoag-
ulated with hirudin (final concentration, 200 U · mL–1) and
the other with EDTA (5 mmol/L).
Materials. Recombinant desulphatohirudin HV1 (r-
hirudin, CGP 39393) with a specific activity of 11.7 ATE ·
mg–1 (antithrombin units per milligram) was dissolved in
0.9% saline solution containing 0.1% polyethylene glycol
600 at a concentration of 20,000 U · mL–1. Fifteen microliters
of this solution was stored in 1.5 mL of Eppendorf micro-
tubes at –20˚C and thawed just before use. Siliconized glass
tubes were used for the EDTA-anticoagulated samples.
Platelet counting and platelet aggregate ratios. Platelets
were counted in whole blood by use of a Coulter T660
counter (Coulter Corporation, Hialeah, Fla). This instrument
also determined the hemoglobin content, which was used to
correct for hemodilution. The hemoglobin was used in pref-
erence to the hematocrit level because the Coulter T660
counter measures the hemoglobin and uses this value to cal-
culate the hematocrit.
There was no difference between the hemoglobin concen-
trations of EDTA- and hirudin-anticoagulated blood at any of
the 3 sampling times (Table I). The hemoglobin concentra-
tion was unaffected by heparinization (P = .4, EDTA; P = .5,
hirudin; n = 21) but fell significantly during extracorporeal
circulation (both P < .0001; n = 21; Friedman analysis of
variance). Corrections for hemodilution were made to the
individual platelet counts both after heparinization and at the
end of cardiopulmonary bypass.
Platelet aggregate ratios were calculated for each individ-
ual set of paired platelet counts, as described by Wu and
Hoak.7 The numerator was the unaggregated or single platelet
count obtained from hirudin-anticoagulated blood, and the
denominator was the total platelet count obtained from
EDTA-anticoagulated blood. This technique measures
changes in the in vivo platelet activation state by serial com-
parisons of existent platelet aggregation ex vivo and is
described in detail elsewhere.4
Statistical analysis. Data are expressed as means ± 1 SD.
All P values quoted in the results are obtained by the
Friedman 2-way analysis of variance. Serial and paired data
were also compared by the Wilcoxon signed-rank test to con-
firm these analyses. All analyses were performed with the use
of Arcus Quickstat Biomedical software retailed by Addison
Wesley Longman trading as Research Solutions.
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tion ex vivo.4 After correction for hemodilution, no fur-
ther reduction was observed at the termination of extra-
corporeal circulation in the earlier of these studies.5
The aim of the current study was to investigate the
effects of heparin and of extracorporeal circulation on
platelet counts and on existent platelet microaggrega-
tion during cardiopulmonary bypass.
Methods
This study was approved by the Royal Infirmary of
Glasgow Research Ethics Committee (Project No. 97SC001
[896] on May 7, 1997). Informed consent was obtained from
all subjects studied. Patients undergoing primary operations
with cardiopulmonary bypass were studied. Patients with dia-
betes receiving warfarin sodium and those dependent on
intravenous nitrates or heparin were excluded. Sixteen men
and 5 women were recruited (total patients, 21); median age
was 63 years (range, 38-79 years). Thirteen patients had iso-
lated coronary revascularization, 5 had isolated single valve
replacement, 2 had coronary revascularization and a single
valve replacement, and 1 had an ascending aortic aneurysm
replaced.
Anesthetic premedication was with temazepam, and induc-
tion was with propofol. Opiate analgesia was used, and main-
tenance anesthesia was with propofol infusion. The anticoag-
ulant used was unfractionated sodium heparin of porcine
mucosal origin (300 U · kg–1; Leo Laboratories, Risborough,
United Kingdom) given through a central venous cannula or
directly into the right atrium just before cannulation.
Anticoagulation was monitored by activated clotting time
with a Hemochron whole-blood coagulation system model
401 (International Technidyne Corporation, Metuchen, NJ).
If the activated clotting time was less than 400 seconds, more
heparin was given. The cardiopulmonary bypass circuit con-
sisted of an Avecor tubing set, an Affinity 40-µm arterial line
filter (Avecor Ltd, Bellshill, Strathclyde, United Kingdom),
and a membrane oxygenator (Duo-COBE; COBE
Laboratories, Division of Gambro BCT, Stockholm, Sweden)
driven by a Stöckert roller pump (Stöckert, Munich,
Germany). The pump prime consisted of 2.0 L of Ringer’s
lactate solution, 50 mmol/L NaHCO3, and 8000 U of sodium
heparin. Flows were maintained at 2.4 L · min–1 · m–2.
Ringer’s lactate solution was used to maintain pump reservoir
volume. If the hematocrit level fell below 25%, packed red
cells were given. The alpha-stat protocol was used for pH
management. The heart was arrested with either antegrade
crystalloid (St Thomas’ Hospital No. 1 solution) or blood car-
dioplegia. Core temperature ranged between 28˚C and 33˚C.
Cardiopulmonary bypass lasted from 57 to 140 minutes
(mean, 84 minutes).
Blood samples were taken from the radial artery line just
before and 5 minutes after heparin administration but before
the onset of extracorporeal circulation. A third sample was
taken at the end of cardiopulmonary bypass before heparin
reversal. This covered the period of greatest platelet loss,2,3
while remaining free of the effects of protamine sulfate on
Table I.  Hemoglobin concentrations
Anticoagulant EDTA Hirudin
Before heparin (g · dL–1) 11.5 ± 1.5 11.4 ± 1.4
After heparin (g · dL–1) 11.3 ± 1.6 11.2 ± 1.8
End cardiopulmonary bypass (g · dL–1) 7.9 ± 1.1* 8.0 ± 1.1*
Data are shown as means ± 1 SD.
*P < .0001 for end cardiopulmonary bypass versus after heparin administra-
tion.
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Results
Uncorrected platelet counts. Platelet counts in
hirudin-anticoagulated blood were consistently lower
than corresponding counts in EDTA-anticoagulated
blood (all P < .0001; n = 21), implying existent aggre-
gation (Table II).
Total platelets. The total platelet count obtained from
EDTA-anticoagulated blood was unaffected by
heparinization (P = .7; n = 21) but fell significantly
during extracorporeal circulation (P < .0001; n = 21;
Table II).
Unaggregated platelets. Heparinization per se signif-
icantly reduced the unaggregated platelet count in
hirudin-anticoagulated blood (P < .0001; n = 21).
During extracorporeal circulation, a further significant
fall was seen (P < .0001; n = 21; Table II).
Dilution-corrected platelet counts
Total platelets. After correction for hemodilution, the
total (EDTA-anticoagulated) platelet count, 198 ± 61 ×
109 · L–1, was unaffected by heparin and stayed at 
197 ± 60 × 109 · L–1 (P = .7 vs before heparin adminis-
tration; n = 21). The count fell during extracorporeal
circulation to 163 ± 52 × 109 ·L –1 (P = .0004 vs after
heparin administration; n = 21).
Unaggregated platelets. Heparinization reduced the
dilution-corrected unaggregated (single) platelet
count in hirudin-anticoagulated blood from 178 ± 62
× 109 · L–1 to 155 ± 60 × 109 · L–1 (P = .0001 vs before
heparin administration; n = 21). Extracorporeal circu-
lation had little additional effect. The final count was
142 ± 48 × 109 · L–1 (P = .6 vs after heparin adminis-
tration; n = 21).
The paired dilution-corrected platelet counts at the 3
time points studied are shown in Fig 1, which demon-
strates the individual variations in the extent of platelet
aggregation and platelet loss. It also underscores the
significance of the differences.
Platelet aggregate ratios. Platelet aggregate ratios
were calculated by using the uncorrected counts to
avoid errors that may be introduced by approxima-
tions used during the corrections. Heparin reduced the
platelet aggregate ratio from 0.90 ± 0.08 to 0.78 ±
0.14 (P < .0001; n = 21). During extracorporeal cir-
culation, the platelet aggregate ratio returned to near
baseline at 0.87 ± 0.11 (P = .0009 vs after heparin
administration and P = .08 vs before heparin adminis-
tration; n = 21; Fig 2).
Discussion
The main findings of this study are as follows. First,
we confirmed our previous observation that hepariniza-
tion for cardiopulmonary bypass increases existent
platelet microaggregation ex vivo.4 Second, during
extracorporeal circulation, the reduction in total
platelet concentration was greater than could be
explained by dilution alone, as seen previously.2,3
Third, despite the reduction in total platelets, the dilu-
tion-corrected unaggregated platelet count did not
change significantly. Finally, the loss of existent
platelet microaggregates accounted for most of the fall
in the dilution-corrected total platelet count during
extracorporeal circulation.
Heparin and platelets. The proaggregatory action of
heparin may be underrated because intravenous
heparin also selectively inhibits platelet macroaggrega-
tion,5,8,9 limiting the total response of platelets to stim-
ulation. Therefore, although intravenous heparin
impairs platelet hemostatic performance, it may inap-
propriately elevate other platelet functions, such as
their inflammatory activity.
Table II.  Summary statistics for uncorrected platelet
counts
Sampling time EDTA Hirudin
Before heparin (×109 · L–1) 198 ± 61 178 ± 62
After heparin (×109 · L–1) 197 ± 58 155 ± 60*
End cardiopulmonary bypass (×109 · L–1) 117 ± 48† 102 ± 44†
Data are shown as means ± 1 SD.
*P < .01 for after heparin administration versus before heparin administration.
†P < .001 for end cardiopulmonary bypass versus after heparin administration.
Fig 1. Total versus unaggregated hemodilution-corrected
platelet counts. EDTA, Total platelet count; hirudin, unaggre-
gated platelet count; CPB, cardiopulmonary bypass.
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Extracorporeal circulation and platelets. The cur-
rent findings suggest that the more active platelets (ie,
those formed into microaggregates) were preferentially
lost from the circulating platelet pool during cardiopul-
monary bypass. Previous workers have also reported a
preferential loss of activated platelets during extracor-
poreal circulation.10 Others observed that increased
platelet responsiveness to in vitro agonists induced by
heparinization was absent after the platelet count fell
during extracorporeal circulation.11
Activated platelets may be preferentially sequestered
in body organs or deposited on the surfaces of the
extracorporeal circuit because they more readily adhere
to foreign surfaces or endotheliocytes than resting
platelets. Conceivably, platelet adherence would be
greatest in areas with low flow rates and a large surface
area/volume ratio, such as the hepatic portal circula-
tion. This would explain why the liver3,12 and the oxy-
genator12,13 are major sites of platelet accumulation
during extracorporeal circulation. Reducing platelet
deposition on the extracorporeal circuit by modifying
its surface may increase platelet accumulation in the
liver and other organs.14
Activated platelets may contribute to the cytokine
production observed in the liver during cardiopul-
monary bypass15 by causing the endotheliocytes to
secrete chemokines and adhesion molecules.16 Platelets
sequestrated in the body during extracorporeal circula-
tion later return to the circulation and have a normal life
span.3 This emphasizes the reversibility of early
platelet responses to stimuli and implies that cycles of
activation and return to the resting state do not affect
platelet longevity.
Hemodilution, which occurs at the onset of extracor-
poreal circulation, reduces the platelet concentration at
the center of the tube more markedly than it does near
the wall.17 Hemodilution also causes marginalization
of erythrocytes,17 which displace the fluid medium and
nearby particles, including platelets, thus increasing
the interactions of these other particles with each other
and the tube walls.18 Hemodilution may therefore
accelerate platelet adherence to vessel and circuit
walls, thus explaining the marked decrease in total cir-
culating platelets occurring at the onset of extracorpo-
real circulation.2,3
These considerations suggest that platelet inhibition
would reduce platelet loss if started before heparin
administration. In clinical studies at this institution,
prostacyclin failed to reduce perioperative bleeding
despite reduced platelet activation19 and deposition on
filters.20 Other investigators report similar findings.21-23
We suggest that this is because inhibiting platelets pre-
serves their numbers, although they remain dysfunc-
tional.
Theoretically, the inhibitory effect of heparin on
platelet macroaggregation,5,8,9 by preventing irre-
versible aggregation, may preserve platelets; however,
platelet loss during extracorporeal circulation may be
largely reversible.3 Furthermore, the current study and
others10 suggest that the loss of circulating platelets
during cardiopulmonary bypass may be more closely
related to shape change and microaggregation, which
precede the macroaggregatory response, which is
inhibited by heparin.
Limitations of the study. The effects of heparin and
extracorporeal circulation were not studied separately.
We were unable to study subjects receiving large doses
of heparin and not undergoing extracorporeal circula-
tion. The information gained from in vitro studies of
the effects of heparin on blood is limited because some
effects of intravenous heparin on platelets are not
reproduced by in vitro heparinization.5,9,24 Intravenous
heparin releases several proteins from the endothelium
into plasma.25 Because these proteins may affect
platelets, information from studies of simulated extra-
corporeal circulation by using blood heparinized in
vitro should be interpreted cautiously.
The effects of heparin may be separated from those
of extracorporeal circulation per se by studies using
models of cardiopulmonary bypass comparing heparin
with alternative anticoagulants. The near-universal use
of heparin to provide anticoagulation for cardiopul-
monary bypass hinders this. Hirudin anticoagulation is
currently being used for clinical cardiopulmonary
bypass in patients with heparin-induced thrombocy-
topenia type II,26 but these patients are an inappropriate
study model because their platelets are already defec-
tive. Workers investigating anticoagulation with selec-
Fig 2. Mean platelet aggregate ratios. Error bars represent 1
SD. CPB, Cardiopulmonary bypass.
tive thrombin inhibitors for cardiopulmonary bypass in
animals report better preservation of platelet num-
bers27,28 and reduced platelet deposition on oxygenator
membranes27 than with heparin. This may be because
selective thrombin inhibitors, like hirudin and arga-
troban, which have no direct inhibitory actions on
platelets, improve platelet preservation by eliminating
the stimulatory actions of heparin.
Conclusion
Heparinization caused platelet activation, which
increased existent platelet microaggregation ex vivo.
Dilution did not explain the full decrease in total
platelet concentration observed during extracorporeal
circulation; the loss of existent platelet microaggre-
gates accounted for most of the deficit. Heparin, by
increasing existent platelet microaggregates, may
therefore promote platelet loss from the circulating
pool during extracorporeal circulation.
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